This is a prospective-retrospective study to determine if the expression of the miRNA's
miR-31-3p and miR-31-5p are prognostic of patient outcomes or predictive of the benefit from
anti-EGFR therapy in stage III Colon Cancer. The present study will utilize FFPE tumor
samples collected from patients enrolled in the PETACC-8 study conducted by the Fédération
Francophone de Cancérologie Digestive (FFCD). This phase 3 clinical trial prospectively
randomized fully resected stage III colon cancer patients to receive adjuvant treatment with
either FOLFOX-4 plus cetuximab or FLOFOX-4 alone.
Phase:
Phase 3
Details
Lead Sponsor:
IntegraGen SA
Collaborators:
Exystat Federation Francophone de Cancerologie Digestive